LabMedica

Download Mobile App
Recent News Expo ADLM 2025 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Methicillin-Resistant Staphylococcus Aureus Test Launched in the U.S.

By LabMedica International staff writers
Posted on 09 Nov 2009
A simple and cost-effective solution for the identification of Methicillin-Resistant Staphylococcus aureus (MRSA) has been launched in the United States.

The product, chromID MRSA, recently received the U.S. Food and Drug Administration (FDA; Silver Spring, MD, USA) 510(k) clearance for the detection of MRSA, one of the most pervasive sources for high-morbidity healthcare-associated infections (HAI) in U.S. hospitals. It is perfectly adapted for general screening processes in healthcare institutions as it provides unambiguous results with a simple protocol. The presence of MRSA is visually identified by green colored colonies on chromID MRSA chromogenic media after a 24-hour incubation period.

chromID MRSA simplifies the detection of MRSA, enabling more economical implementation of prevention measures. chromID MRSA agar is a selective and differential chromogenic medium for the qualitative detection of nasal colonization of MRSA. The tool aids in the prevention and control of MRSA infections in healthcare settings. A bioMerieux (Durham, NC, USA) product, chromID MRSA has been widely adopted throughout Europe over the past few years.

bioMérieux's objective was to provide customers with a flexible and complete solution to effectively manage MRSA, spanning manual and automated techniques, from culture-based methods to molecular biology. A more comprehensive approach to containing MRSA needs to be taken, involving critical functions such as resistance detection, organism strain typing for outbreak investigations, hygiene, and antibiotic stewardship programs.

Identifying resistance and helping clinicians to obtain clear actionable information so they can begin effective antibiotic therapy as early as possible is an integral part of bioMérieux's recently launched the Solutions to Manage the Antimicrobial Resistance Threat (S.M.A.R.T.) campaign. The initiative promises to create more educational resources for the lab and to provide healthcare professionals with relevant tools to identify, monitor, prevent, and track resistance.

Related Links:
U.S. Food and Drug Administration
bioMerieux
Solutions to Manage the Antimicrobial Resistance Threat


New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
Serological Pipet Controller
PIPETBOY GENIUS
New
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
New
Pipette
Accumax Smart Series

Latest Microbiology News

Saliva Test Detects Implant-Related Microbial Risks
09 Nov 2009  |   Microbiology

New Platform Leverages AI and Quantum Computing to Predict Salmonella Antimicrobial Resistance
09 Nov 2009  |   Microbiology

Early Detection of Gut Microbiota Metabolite Linked to Atherosclerosis Could Revolutionize Diagnosis
09 Nov 2009  |   Microbiology